For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Viridian Therapeutics Inc (NASDAQ: VRDN) closed the day trading at $23.01 up 3.32% from the previous closing price of $22.27. In other words, the price has increased by $3.32 from its previous closing price. On the day, 1.65 million shares were traded. VRDN stock price reached its highest trading level at $23.07 during the session, while it also had its lowest trading level at $21.79.
Ratios:
For a better understanding of VRDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1879051136 and an Enterprise Value of 1527661056. For the stock, the TTM Price-to-Sale (P/S) ratio is 6263.50 while its Price-to-Book (P/B) ratio in mrq is 5.76. Its current Enterprise Value per Revenue stands at 5008.725 whereas that against EBITDA is -4.117.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.77, which has changed by -0.078863084 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 18.02%, while the 200-Day Moving Average is calculated to be 38.87%.
Shares Statistics:
Over the past 3-months, VRDN traded about 784.40K shares per day on average, while over the past 10 days, VRDN traded about 978050 shares per day. A total of 81.65M shares are outstanding, with a floating share count of 73.55M. Insiders hold about 9.93% of the company’s shares, while institutions hold 106.20% stake in the company. Shares short for VRDN as of 1759190400 were 10235828 with a Short Ratio of 13.05, compared to 1756425600 on 11571282. Therefore, it implies a Short% of Shares Outstanding of 10235828 and a Short% of Float of 13.089999999999998.
Earnings Estimates
A comprehensive evaluation of Viridian Therapeutics Inc (VRDN) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.42 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$2.96 and -$4.97 for the fiscal current year, implying an average EPS of -$4.05. EPS for the following year is -$3.97, with 11.0 analysts recommending between -$2.9 and -$4.99.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $54.5M in the next fiscal year. The high estimate is $153M and the low estimate is $300k.
